Sensory Organ Drugs - United Kingdom

United Kingdom

The United Kingdom's Sensory Organ Drugs market is projected to reach a revenue of US$0.79bn in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2028) of 6.86%, leading to a market volume of US$1.03bn by 2028.
When compared globally, United States will generate the highest revenue with US$15,360.00m in 2024.
The United Kingdom has seen a growing demand for sensory organ drugs, particularly in the field of ophthalmology.

Key regions: India, China, Japan, Canada, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The market for Sensory Organ Drugs in the United Kingdom has been experiencing steady growth over the past few years.

Customer preferences: Customers in the United Kingdom have shown a growing interest in sensory organ drugs due to an aging population and an increase in eye-related disorders such as macular degeneration and glaucoma. Additionally, the rise in allergies and respiratory illnesses has led to an increase in demand for nasal sprays and other related drugs.

Trends in the market: In recent years, there has been a shift towards the development of more personalized treatments for sensory organ disorders in the United Kingdom. This has led to an increase in research and development spending by pharmaceutical companies in the country. Additionally, the rise of e-commerce and online pharmacies has made it easier for customers to access these drugs, leading to an increase in sales.

Local special circumstances: The National Health Service (NHS) plays a significant role in the sensory organ drugs market in the United Kingdom. The NHS provides free healthcare to all residents, which includes prescription drugs. As a result, many customers prefer to obtain their sensory organ drugs through the NHS rather than purchasing them from private pharmacies.

Underlying macroeconomic factors: The United Kingdom's economy has been experiencing slow growth in recent years, which has led to an increase in government spending on healthcare. This has had a positive impact on the sensory organ drugs market, as the government has increased funding for research and development in this area. Additionally, the United Kingdom's exit from the European Union has created uncertainty in the market, which has led to an increase in demand for locally produced drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.